STADA and Xbrane welcome CHMP positive opinion for ranibizumab biosimilar candidate- Ximluci.
Partners STADA Arzneimittel AG and Xbrane Biopharma AB announce that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Ximluci, a biosimilar candidate referencing Lucentis (ranibizumab)
Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for the treatment of retinal vascular disorders, which are a leading cause of blindness. Ximluci has been recommended for approval in the European Union (EU) for the treatment of wet age-related macular degeneration (AMD), diabetic macular oedema (DME), diabetic retinopathy (PDR), retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularization (CNV).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins